Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement

201280 citationsJournal Articlebronze Open Access

Authors

Pierre‐Yves Salaün · Inserm

L. Campion · Institut de Cancérologie de l'Ouest

Claire Bournaud · Lyon College

Alain Faivre-Chauvet · Inserm

Jean‐Philippe Vuillez · Laboratoire de Radiopharmaceutiques Biocliniques

David Taïeb · Assistance Publique Hôpitaux de Marseille

C. Ansquer

Abstract

pRAIT showed antitumor activity, with manageable hematologic toxicity in progressive MTC. Increased biomarker DT after treatment correlated with increased OS.

Topics & Keywords

Thyroid Cancer Diagnosis and Treatment Radiopharmaceutical Chemistry and Applications Neuroendocrine Tumor Research Advances

Publication Details

Published in: Journal of Nuclear Medicine

Volume 53, Issue 8, pp. 1185-1192

DOI: 10.2967/jnumed.111.101865

Field-Weighted Citation Impact: 5.32

Command Palette

Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement

Authors

Abstract

Topics & Keywords

Publication Details